LONGEVA.

Humanin: adverse events and evidence limits

In Moreno Ayala and colleagues’ study, administering humanin to mice with triple-negative breast cancer increased tumour growth and lung metastases. It also weakened doxorubicin’s antitumour effect in that model. [1]

This is a preclinical risk signal, not an established human cancer-complication rate. The findings concern humanin and that tumour model; they cannot automatically be transferred to the HNG analogue or interpreted as safety evidence in other settings. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Increased tumour growth and lung metastasesMice with triple-negative breast cancerObserved in this model; a preclinical risk signal, not an established human cancer-complication rate[1]
Weakened antitumour effect of doxorubicinThe same mouse tumour modelObserved in the model; no human frequency established[1]

References

  1. Moreno Ayala MA, Gottardo MF, Zuccato CF, Pidre ML, Nicola Candia AJ, Asad AS, Imsen M, Romanowski V, Creton A, Isla Larrain M, Seilicovich A, Candolfi M. (2020). Humanin Promotes Tumor Progression in Experimental Triple Negative Breast Cancer https://doi.org/10.1038/s41598-020-65381-7.